MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Inovio Pharmaceuticals (INO) Prostate Cancer Vaccine Shows Success in Primate Trial  0 comments
    Jun 30, 2011 1:38 PM | about stocks: INO
    Inovio Pharmaceuticals Inc., a leading developer of therapeutic and preventive vaccines, today announced that its SynCon ™ therapeutic DNA vaccine (INO-5150) for prostate cancer demonstrated positive immune responses in monkeys.
    The company said the results support similarly strong, antigen-specific and sustainable T cell levels in previously reported data from earlier animal studies. Inovio said the new data reinforces its plan to a start phase I clinical trial for INO-5150 by the middle of next year.
    Dr. J. Joseph Kim, Ph.D., president & CEO of Inovio, emphasized the potential of the vaccine in human models.
    “The immune response data achieved by our SynCon™ prostate cancer vaccine in this large animal study is exceptional. It reinforces the repeatedly and consistently strong, long-lasting immune responses achieved by Inovio’s DNA vaccine platform against multiple cancers as well as other diseases,” Dr. Kim stated in the press release. “We are optimistic about the potential of this therapeutic vaccine in our planned prostate cancer human study and broadly speaking for cancers in general, including our currently progressing cervical cancer and leukemia phase II clinical studies.”
    Inovio is currently manufacturing clinical grade INO-5150 with the goal of launching its planned phase I study in mid-2012. The company plans on enrolling a total of 148 patients across 25 study centers in the US., Korea, South Africa, Australia and Canada.
    Inovio is currently conducting a phase II study for its cervical cancer vaccine. The randomized, placebo controlled, double blind study as designed to evaluate the effects of VGX-3100 treatment on the clearance of moderate or severe cervical intraepithelial neoplasia (CIN 2/3) cervical lesions.
    For more information visit inovio.com
    Please see disclaimer on the MissionIR website www.missionir.com/disclaimer.html 
    Stocks: INO
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.